Back to List View Graph View

Glucocorticoid

Glucocorticoids are a class of steroid hormones and widely used anti-inflammatory and immunosuppressive agents that act primarily through the glucocorticoid receptor.

Where the papers sit

11 papers from the last 6 months study glucocorticoid directly · updated from PubMed 14 Nov 2026

Study type 0 clinical trials · 9 observational · 1 human data · 1 unclassified

Themes 3 themes · 1 paradigm shift · 1 new direction

  • Steroid Strategies in Immune Disease

    Glucocorticoid treatment is being reconsidered across immune diseases, but this group has no unified therapeutic direction. In giant cell arteritis, tocilizumab and methotrexate are compared with steroid monotherapy against relapse and serious infection. Other papers examine Th17 glucocorticoid sensing, B-cell receptor repertoires, prolonged chronic GVHD treatment with belumosudil, or steroid maintenance in ANCA-associated vasculitis. These findings support disease-specific steroid-sparing and biomarker questions rather than one shared conclusion.

    6 papers · 54.5%

  • Rheumatoid Arthritis Steroid Exposure

    Rheumatoid arthritis work is moving toward more precise measurement of glucocorticoid exposure and earlier steroid-sparing decisions. National registers and hospital records are being used to compare exposure algorithms during the first treatment year. Dynamic platelet-to-lymphocyte ratio adds predictive information beyond ESR and CRP for identifying patients likely to avoid or reduce steroids. Whether these measures improve outcomes or simply classify exposure remains open.

    3 papers · 27.3%

  • Lupus Comorbidity and Damage

    Early systemic lupus erythematosus is being framed as a multimorbidity disease in which flares and glucocorticoid exposure shape long-term outcomes. Cardiopulmonary and musculoskeletal comorbidities accumulate quickly, especially in patients with frequent flares. Neuropsychiatric damage is linked to exposure over time and to limited social support. The emphasis is shifting toward early risk stratification and glucocorticoid minimization, although these studies identify predictors rather than test a specific intervention.

    2 papers · 18.2%

PARADIGM SHIFT

Ongoing glucocorticoid exposure is not required for effective vasculitis maintenance and may be replaceable by steroid-sparing treatment

The ANCA-associated vasculitis maintenance cohort found no benefit from adding low-dose glucocorticoids for preventing major relapse, hospitalisation, or damage accumulation, while the giant cell arteritis comparison found glucocorticoid plus tocilizumab to be the only independently protective regimen and to reduce the composite burden relative to glucocorticoid monotherapy. Together, these findings replace the assumption that continued glucocorticoid treatment is necessary during vasculitis maintenance with a model in which steroid-sparing therapy can preserve control while reducing glucocorticoid exposure 42342286Jun 42365805Jun.

NEW DIRECTION

Glucocorticoid is an intrinsic homeostatic signal that maintains a non-inflammatory Th17 cell state

The Th17-cell model identified cell-intrinsic glucocorticoid production through CYP11A1 and sensing through the glucocorticoid receptor as a self-maintaining circuit that distinguishes homeostatic from pro-inflammatory Th17 cells. This assigns glucocorticoid a role beyond administered therapy, exposure, or treatment response: it is an endogenous regulator of immune-cell state and tissue homeostasis 42285103Jun.

Papers

The 11 papers from the last 6 months that study glucocorticoid directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Steroid Strategies in Immune Disease (6)
  1. Peripheral B-cell receptor immunoglobulin heavy chain repertoire as a potential biomarker for frequently relapsing nephrotic syndrome in children. Renal failure · 27 Aug 2026 PMID 42655963
  2. Glucocorticoid in giant cell arteritis: real-world treatment patterns over time and associated burden in a nationwide hospital-based study within the French health insurance database. RMD open · 7 Jul 2026 PMID 42414038
  3. Glucocorticoid monotherapy versus combination with methotrexate or tocilizumab in giant cell arteritis: efficacy and safety at 78 weeks in a retrospective cohort study. Medicina clinica · 28 Jun 2026 PMID 42365805
  4. No benefit of adding glucocorticoids to maintenance treatment in reducing the risk of major relapses in ANCA-associated vasculitis: real life data from a longitudinal cohort study. RMD open · 24 Jun 2026 PMID 42342286
  5. A cell-intrinsic glucocorticoid biosynthesis and sensing circuit maintains a homeostatic Th17 cell state. Immunity · 12 Jun 2026 PMID 42285103
  6. Belumosudil in the Management of Heavily Pretreated Prolonged Chronic GVHD: A Retrospective Multicenter Real-World Study. Hematological oncology · 27 May 2026 PMID 42198791
Rheumatoid Arthritis Steroid Exposure (3)
  1. Comparing algorithms for estimating glucocorticoid exposure in Danish patients with rheumatoid arthritis: a study using national registers and DANBIO data. European journal of clinical pharmacology · 8 Nov 2026 PMID 43000455
  2. Incremental Predictive Value of Dynamic Platelet-to-Lymphocyte Ratio Beyond ESR and CRP for Glucocorticoid Sparing in Rheumatoid Arthritis: A Multi-Center Retrospective Cohort Study. Pharmacotherapy · 23 Oct 2026 PMID 42910477
  3. Glucocorticoid use among patients with rheumatoid arthritis during the first year of treatment-a cohort study. Rheumatology international · 12 Jun 2026 PMID 42283855
Lupus Comorbidity and Damage (2)
  1. Early SLE may follow a fast comorbidity/multimorbidity trajectory associated with flare burden and glucocorticoid exposure. RMD open · 23 Sept 2026 PMID 42778333
  2. Glucocorticoid exposure and social support deficits as longitudinal predictors of long-term neuropsychiatric damage in SLE: insights from the LUMINA cohort (LXXXIII). Lupus science & medicine · 22 Jul 2026 PMID 42486615

By study type

Observational studies and case reports (9)
  1. Comparing algorithms for estimating glucocorticoid exposure in Danish patients with rheumatoid arthritis: a study using national registers and DANBIO data. European journal of clinical pharmacology · 8 Nov 2026 PMID 43000455
  2. Incremental Predictive Value of Dynamic Platelet-to-Lymphocyte Ratio Beyond ESR and CRP for Glucocorticoid Sparing in Rheumatoid Arthritis: A Multi-Center Retrospective Cohort Study. Pharmacotherapy · 23 Oct 2026 PMID 42910477
  3. Peripheral B-cell receptor immunoglobulin heavy chain repertoire as a potential biomarker for frequently relapsing nephrotic syndrome in children. Renal failure · 27 Aug 2026 PMID 42655963
  4. Glucocorticoid exposure and social support deficits as longitudinal predictors of long-term neuropsychiatric damage in SLE: insights from the LUMINA cohort (LXXXIII). Lupus science & medicine · 22 Jul 2026 PMID 42486615
  5. Glucocorticoid in giant cell arteritis: real-world treatment patterns over time and associated burden in a nationwide hospital-based study within the French health insurance database. RMD open · 7 Jul 2026 PMID 42414038
  6. Glucocorticoid monotherapy versus combination with methotrexate or tocilizumab in giant cell arteritis: efficacy and safety at 78 weeks in a retrospective cohort study. Medicina clinica · 28 Jun 2026 PMID 42365805
  7. No benefit of adding glucocorticoids to maintenance treatment in reducing the risk of major relapses in ANCA-associated vasculitis: real life data from a longitudinal cohort study. RMD open · 24 Jun 2026 PMID 42342286
  8. Glucocorticoid use among patients with rheumatoid arthritis during the first year of treatment-a cohort study. Rheumatology international · 12 Jun 2026 PMID 42283855
  9. Belumosudil in the Management of Heavily Pretreated Prolonged Chronic GVHD: A Retrospective Multicenter Real-World Study. Hematological oncology · 27 May 2026 PMID 42198791
Human data, design not indexed (1)
  1. Early SLE may follow a fast comorbidity/multimorbidity trajectory associated with flare burden and glucocorticoid exposure. RMD open · 23 Sept 2026 PMID 42778333
Unclassified: not yet indexed with MeSH (1)
  1. A cell-intrinsic glucocorticoid biosynthesis and sensing circuit maintains a homeostatic Th17 cell state. Immunity · 12 Jun 2026 PMID 42285103